filmov
tv
ctDNA Detection after neoadjuvant CT significantly associated with disease recurrence in early TNBC
Показать описание
GS5-02 Detection of circulating tumor DNA (ctDNA) after neoadjuvant chemotherapy is significantly associated with disease recurrence in early-stage triple-negative breast cancer (TNBC): Preplanned correlative results from clinical trial BRE12-158
Milan Radovich, Guanglong Jiang, Christopher Chitambar, Rita Nanda, et al.
Recorded @ the San Antonio Breast Cancer Symposium Press Briefing December 13, 2019.
Milan Radovich, Guanglong Jiang, Christopher Chitambar, Rita Nanda, et al.
Recorded @ the San Antonio Breast Cancer Symposium Press Briefing December 13, 2019.
0:17:21
ctDNA Detection after neoadjuvant CT significantly associated with disease recurrence in early TNBC
0:01:51
A Positive ctDNA Test after Adjuvant Therapy: 2023 Best of GI
0:01:24
Detection of ctDNA post neoadjuvant chemo is associated with disease relapse in early breast cancer
0:05:46
Value of Circulating Tumor DNA After Neoadjuvant Chemotherapy for Triple Negative Breast Cancer
0:02:51
Personalized ctDNA during neoadjuvant therapy in pts with early-stage breast cancer
0:58:52
ctDNA and MRD | 2023 Best of GI Cancer Conference
1:05:21
ctDNA and MRD Testing | Colorectal Cancer Care Tools for Surveillance
0:01:28
ctDNA testing in pancreatic cancer and other upper GI malignancies
0:01:23
Role of ctDNA in MRD
0:03:25
Understand ctDNA Testing
0:01:36
ctDNA assay for detection of recurrent disease in patients with early-stage breast cancer
0:16:11
ctDNA in Breast Cancer | 2023 COEDS Discussion Series Fort Lauderdale
0:02:28
Circulating Tumor DNA (ctDNA) in Breast Cancer: 2023 COEDS Ft Lauderdale Conference
0:03:26
Using ctDNA to predict recurrence and response in colorectal cancer
0:06:55
The prognostic value of ctDNA in NSCLC treated with neoadjuvant chemoimmunotherapy
0:01:26
Potential role of ctDNA for early-stage breast cancer
0:13:28
What is ctDNA? How is it Helpful?
0:22:26
Current status and perspectives on liquid biopsies in mCRC
0:04:26
Fundamentals of ctDNA
0:46:19
The use of ctDNA for molecular residual disease assessment and Immunotherapy Monitoring in NSCLC
1:46:57
Dr. Nicholas Turner | What ctDNA Can Tell Us | SABCS 2022 | Educational Session
0:46:53
ctDNA and MRD: Who, When, and Then What? | 2022 Evolution Conference
1:25:24
Expediting Drug Development: Use of ctDNA as an Early Endpoint
0:02:13
Dr. Bach on Examining ctDNA in CRC
Комментарии